They showed that the drugs protect against corona infection and could prevent serious disease progression after infection.
For example, Eli Lilly’s antibodies have reduced the number of hospitalizations due to Covid 19 disease by 70 percent. Regeneron’s remedy prevented symptomatic courses.
The US pharmaceutical companies Eli Lilly and Regeneron have published the first interim results on the effectiveness of their drugs against Covid-19. After that, their antibody cocktails can protect against infection with the coronavirus and prevent severe disease progression after infection. Both companies referred to interim results from clinical trials on their drugs in development.
The cocktails contain neutralizing monoclonal antibodies developed against the new coronavirus. They are supposed to prevent a virus from docking on human cells and thus neutralize it.
Regeneron markets its casirivimab and imdevimab antibodies as Regen-Cov, Lilly’s antibodies are called Bamlanivimab and Etesevimab. Both had drugs by the US Food and Drug Administration Obtained an emergency license in November.
According to the communication from Eli Lilly a single injection of bamlanivimab and etesevimab significantly reduced hospitalizations and deaths from Covid-19. In total, the clinical study includes 1,035 patients who became infected with the coronavirus but had not yet developed any severe symptoms. One group received the antibody treatment, the other a placebo.
While 36 people in the placebo group had to be treated in hospital, there were only eleven in the antibody group. The antibody administration reduced the risk of hospitalization by 70 percent. There were a total of ten deaths among the participants, all of which were attributable to the placebo group.
So far only the antibody Bamlanivimab from Lilly has received emergency approval from the FDA. In a separately published study However, it was shown that only a combination with the antibody etesevimab resulted in a significant reduction in viral load.
No symptoms after an antibody cocktail from Regeneron
Regeneron also reported of positive interim results. The clinical study for his cocktail called Regen-Cov examines the effectiveness of the drug as a so-called post-exposure prophylaxis (PEP). This type of passive immunization should – in contrast to active immunization through a vaccination – bring about short-term immunity via the administration of antibodies. People who lived in a household with a person suffering from Covid-19 were therefore allowed to participate in the study. The interim results include the data from 409 of the more than 2,000 study participants.
According to Regeneron, none of the 186 subjects with antibodies developed symptomatic Covid-19 disease, while eight of the 223 participants in the placebo control group had symptoms. If you add the asymptomatic cases, it shows that Regen-Cov reduces the risk of infection by around 50 percent, according to the press release.
The maximum viral load was also reduced in the antibody group. In addition, the disease lasted a maximum of a week after treatment with Regen-Cov. After that, all participants treated with medication had a negative test result again. In the placebo group, on the other hand, illnesses lasted three to four weeks.
The final study results remain to be seen. However, the interim results promise that the antibody cocktails will be effective in combating the coronavirus. Regeneron pointed out that the drug is effective not only when administered intravenously but also subcutaneously, which could reduce the cost of therapy. In addition, the pharmaceutical company gave in another press release indicated that the cocktail in the laboratory was also effective against the new variants of the coronavirus, B.1.1.7 and B.1.351.